Astrana Health, Inc.

Astrana Health, Inc.

ASTHยทNASDAQ

$36.70

-2.8%
HealthcareMedical - Care Facilities

Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians and extenders, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was incorporated in 1985 and is headquartered in Alhambra, California.

At a Glance

Live Snapshot
Market Cap$1.82B
EPS0.4600
P/E Ratio79.78
Earnings Date08/06/2026
asth

Astrana Health, Inc. Street Expectations Map

ASTH ยท NASDAQ

Wall Street analysts project that ASTH stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 44.60, with estimates ranging from a low of 40.00 to a high of 50.00.

Lowest Target
40.00
8.99%
Consensus Target
44.60
21.53%
Highest Target
50.00
36.24%

The consensus 1-year price target stands at 44.60, with estimates ranging from a low of 40.00 to a high of 50.00.

Analyst Consensus Analysis

Upside Potential

+21.5%

Strong upside potential. Consensus indicates attractive return opportunity with favorable risk-reward profile.

Analyst Agreement

22.4% spread

Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.

Analyst Conviction

Very High

Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.

Market Sentiment Insight

Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.

asth

Astrana Health, Inc. Forward Estimates of Revenue

ASTH ยท NASDAQ
Latest Revenue
3.18B
FY 2025
Avg Estimate
3.97B
FY 2026
Estimate Range
3.68B - 4.19B
Analyst Spread

Forward Growth Analysis

Projected Growth+24.8%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage7 Analysts

Moderate coverageโ€”sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread13%

Reasonable estimate spread indicates general agreement with normal forecast variance.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.

asth

Astrana Health, Inc. Forward Estimates of Net Income

ASTH ยท NASDAQ
Latest Net Income
22.49M
FY 2025
Avg Estimate
61.95M
FY 2026
Estimate Range
1.82M - 129.95M
Analyst Spread

Forward Growth Analysis

Projected Growth+175.5%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage7 Analysts

Moderate coverageโ€”sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread207%

Wide estimate range reveals significant forecast uncertainty and potential volatility.

OutlookNeutral

Mixed signalsโ€”some positive indicators offset by concerns about growth or uncertainty.

Key Insight

High forecast uncertainty: Wide estimate range indicates analysts struggling to predict outcomesโ€”suggests elevated risk and potential volatility.

asth

Astrana Health, Inc. Forward Estimates of EPS

ASTH ยท NASDAQ
Latest EPS
0.46
FY 2025
Avg Estimate
$1.37
FY 2026
Estimate Range
$0.04 - $2.69
Analyst Spread

Forward Growth Analysis

Projected Growth+198.4%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage4 Analysts

Limited coverage may indicate reduced institutional interest or information availability.

Estimate Spread194%

Wide estimate range reveals significant forecast uncertainty and potential volatility.

OutlookNeutral

Mixed signalsโ€”some positive indicators offset by concerns about growth or uncertainty.

Key Insight

Limited coverage with volatile estimates: Few analysts covering despite significant projected changes may indicate information gaps or emerging risks.

asth

Astrana Health, Inc. Forward Estimates of EBIT

ASTH ยท NASDAQ
Latest EBIT
78.53M
FY 2025
Avg Estimate
280.40M
FY 2026
Estimate Range
260.01M - 295.70M
Analyst Spread

Forward Growth Analysis

Projected Growth+257.1%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage7 Analysts

Moderate coverageโ€”sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread13%

Reasonable estimate spread indicates general agreement with normal forecast variance.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.

asth

Astrana Health, Inc. Forward Estimates of EBITDA

ASTH ยท NASDAQ
Latest EBITDA
124.27M
FY 2025
Avg Estimate
370.95M
FY 2026
Estimate Range
343.97M - 391.18M
Analyst Spread

Forward Growth Analysis

Projected Growth+198.5%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage7 Analysts

Moderate coverageโ€”sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread13%

Reasonable estimate spread indicates general agreement with normal forecast variance.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.

asth

Astrana Health, Inc. Forward Estimates of SG&A Expense

ASTH ยท NASDAQ
Latest SG&A Expense
217.26M
FY 2025
Avg Estimate
275.59M
FY 2026
Estimate Range
255.55M - 290.62M
Analyst Spread

Forward Growth Analysis

Projected Growth+26.9%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage7 Analysts

Moderate coverageโ€”sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread13%

Reasonable estimate spread indicates general agreement with normal forecast variance.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.

asth

Astrana Health, Inc. Insider Positioning

ASTH ยท NASDAQ

During the last 12 months, insiders have purchased $364K worth of ASTH shares, with no selling activity reported.

3 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

3-6 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

6-9 Months

Bought

20.0K

364.00K

Sold

0

0.00

Net Activity

+364K

+$364K

9-12 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

Top Buyers

1
ML

Marsh Linda

Director

20.0K sharesโ€ข1 transactions

$364K

Top Sellers

No selling activity

Insider Activity Analysis

Net Insider Sentiment

Bullish

Strong bullish signal with $364K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.

Buy/Sell Ratio

โˆž:1

Perfect buy/sell ratio. Only buying activity with zero sellingโ€”the most bullish possible insider signal.

Insider Participation

High Buying

1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.

Insider Activity Insight

Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.